New pill for advanced cancers enters first human tests
NCT ID NCT04045496
First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 14 times
Summary
This early-phase study tested an experimental oral drug called JAB-3312 in 40 adults with advanced solid tumors (such as lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. Participants took the drug daily in 21-day cycles, and researchers monitored for any serious reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HealthONE Clinic Services Oncology-Hematology
Denver, Colorado, 80202, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Washington University School of Medicine
Seattle, Washington, 63110, United States
Conditions
Explore the condition pages connected to this study.